Sun Pharma to acquire US-based Organon in US$ 11.75 billion deal
- IBEF
- April 28, 2026
Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, has announced the acquisition of US-based healthcare company Organon & Co. in an all-cash deal valued at Rs. 10.86 lakh crore (US$ 11.75 billion), marking one of the largest overseas acquisitions by an Indian pharmaceutical firm. The transaction, approved by the boards of both companies, involves a cash payment of Rs. 1,294.16 (US$ 14) per share to Organon shareholders and is expected to close by early 2027, subject to regulatory and shareholder approvals. The acquisition significantly strengthens Sun Pharma’s global footprint by adding Organon’s portfolio of over 70 products across women’s health, general medicines and biosimilars, with a presence in more than 140 countries. The combined entity is expected to emerge as a leading global player, including a top-three position in women’s health and a strong entry into the biosimilars segment.
The deal is also projected to enhance Sun Pharma’s scale, diversify its therapeutic portfolio and strengthen its position in high-growth speciality segments such as dermatology, oncology and biologics. The acquisition will be financed through a mix of internal accruals and committed bank financing, with expected synergies and improved profitability over the medium term. Overall, the transaction underscores India’s growing presence in global pharmaceutical mergers and acquisitions, positioning Sun Pharma as a stronger and more diversified global healthcare player.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
